Peel Hunt Reconfirmed Kaz Minerals PLC (LON:KAZ) As Add; Has PT Of GBX 930.00; Last Week Spark Therapeutics, Inc. (ONCE) Coverage

They currently have a GBX 930.00 target price on Kaz Minerals PLC (LON:KAZ). Peel Hunt’s target would suggest a potential upside of 13.72% from the company’s previous close. This was shown in a research note on Wednesday, 31 January.

Among 22 analysts covering Spark Therapeutics (NASDAQ:ONCE), 15 have Buy rating, 2 Sell and 5 Hold. Therefore 68% are positive. Spark Therapeutics has $107 highest and $37 lowest target. $76.63’s average target is 29.88% above currents $59 stock price. Spark Therapeutics had 58 analyst reports since August 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 2 by Cowen & Co. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Buy” rating by Bernstein on Wednesday, December 13. The rating was maintained by Roth Capital with “Buy” on Monday, October 5. The rating was upgraded by Wedbush to “Hold” on Tuesday, December 12. Stifel Nicolaus maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) rating on Monday, June 26. Stifel Nicolaus has “Buy” rating and $7700 target. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Hold” rating given on Tuesday, December 12 by UBS. The rating was downgraded by Leerink Swann on Tuesday, December 12 to “Hold”. Goldman Sachs initiated the shares of ONCE in report on Wednesday, March 30 with “Neutral” rating. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Hold” rating given on Friday, August 21 by Zacks. Chardan Capital Markets initiated Spark Therapeutics, Inc. (NASDAQ:ONCE) on Wednesday, December 23 with “Neutral” rating. See Spark Therapeutics, Inc. (NASDAQ:ONCE) latest ratings:

25/01/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $61 New Target: $64 Maintain
25/01/2018 Broker: Wedbush Rating: Sell New Target: $40.0 Maintain
24/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $66.0 Maintain
24/01/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $105.0 Maintain
16/01/2018 Broker: Wedbush Old Rating: Neutral New Rating: Underperform Downgrade
03/01/2018 Broker: Cowen & Co Rating: Buy New Target: $85.0 Maintain
02/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $67.0 Maintain
14/12/2017 Broker: Goldman Sachs Rating: Hold New Target: $58.0 Downgrade
13/12/2017 Broker: Bernstein Rating: Buy New Target: $71.0 Maintain
12/12/2017 Broker: Wedbush Rating: Hold Upgrade

KAZ Minerals PLC, together with its subsidiaries, engages in mining, processing, and sale of copper concentrates primarily in Kazakhstan and Kyrgyzstan. The company has market cap of 3.67 billion GBP. It operates through East Region, Bozymchak, Bozshakol, and Aktogay divisions. It has a 12.7 P/E ratio. The firm operates four underground mines and three concentrators located in the eastern region of Kazakhstan; Bozymchak copper-gold open pit mine located in Kyrgyzstan; the Bozshakol open pit mine in the Pavlodar region of Kazakhstan; and Aktogay open pit located in eastern Kazakhstan.

Among 22 analysts covering Kaz Minerals PLC (LON:KAZ), 11 have Buy rating, 5 Sell and 6 Hold. Therefore 50% are positive. Kaz Minerals PLC has GBX 1020 highest and GBX 50 lowest target. GBX 569.52’s average target is -30.73% below currents GBX 822.2 stock price. Kaz Minerals PLC had 253 analyst reports since July 23, 2015 according to SRatingsIntel. HSBC upgraded KAZ Minerals plc (LON:KAZ) rating on Wednesday, April 19. HSBC has “Hold” rating and GBX 450 target. The stock of KAZ Minerals plc (LON:KAZ) has “Add” rating given on Wednesday, January 31 by Peel Hunt. On Tuesday, October 13 the stock rating was maintained by Credit Suisse with “Neutral”. UBS maintained it with “Buy” rating and GBX 340 target in Tuesday, October 11 report. Morgan Stanley upgraded it to “Equal Weight” rating and GBX 380 target in Friday, February 3 report. The firm has “Outperform” rating by BNP Paribas given on Friday, February 24. Numis Securities maintained it with “Hold” rating and GBX 200 target in Wednesday, August 5 report. The company was maintained on Friday, January 29 by Deutsche Bank. Macquarie Research maintained the shares of KAZ in report on Tuesday, May 17 with “Outperform” rating. The company was maintained on Wednesday, February 3 by Peel Hunt.

The stock decreased 0.34% or GBX 2.8 during the last trading session, reaching GBX 822.2. About 379,078 shares traded. KAZ Minerals plc (LON:KAZ) has 0.00% since January 31, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 2.94 in Q3 2017. Its up 1.13, from 1.81 in 2017Q2. It improved, as 17 investors sold Spark Therapeutics, Inc. shares while 19 reduced holdings. 46 funds opened positions while 60 raised stakes. 33.64 million shares or 23.59% more from 27.22 million shares in 2017Q2 were reported. State Street reported 1.19 million shares. Pictet Asset Ltd stated it has 131,471 shares or 0.03% of all its holdings. Aperio Gru Ltd Liability Com invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Blackrock invested 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). California Pub Employees Retirement System owns 0.01% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 39,800 shares. Prudential Financial stated it has 2,675 shares. Voya Inv Mgmt Ltd Co holds 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE) or 12,203 shares. Clearbridge Investments Ltd Liability Corporation reported 667,952 shares stake. Great West Life Assurance Can holds 3,939 shares. 20,415 are owned by Manufacturers Life Ins The. Sei Co invested in 93 shares or 0% of the stock. State Board Of Administration Of Florida Retirement stated it has 10,064 shares. Ubs Asset Americas Inc has 0.01% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 137,603 shares. Viking Global Invsts L P, a Connecticut-based fund reported 243,140 shares. Focused Wealth Management stated it has 750 shares.

The stock decreased 0.64% or $0.38 during the last trading session, reaching $59. About 673,751 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 13.53% since January 31, 2017 and is uptrending. It has underperformed by 3.17% the S&P500.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $2.18 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.